ZA201704328B - Glucagon derivatives - Google Patents

Glucagon derivatives

Info

Publication number
ZA201704328B
ZA201704328B ZA2017/04328A ZA201704328A ZA201704328B ZA 201704328 B ZA201704328 B ZA 201704328B ZA 2017/04328 A ZA2017/04328 A ZA 2017/04328A ZA 201704328 A ZA201704328 A ZA 201704328A ZA 201704328 B ZA201704328 B ZA 201704328B
Authority
ZA
South Africa
Prior art keywords
glucagon derivatives
glucagon
derivatives
Prior art date
Application number
ZA2017/04328A
Other languages
English (en)
Inventor
Sung Youb Jung
Young Jin Park
Jong Suk Lee
Jae Hyuk Choi
Chang Ki Lim
Se Chang Kwon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of ZA201704328B publication Critical patent/ZA201704328B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2017/04328A 2014-12-30 2017-06-26 Glucagon derivatives ZA201704328B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140193691A KR102418477B1 (ko) 2014-12-30 2014-12-30 글루카곤 유도체
PCT/KR2015/014481 WO2016108617A1 (en) 2014-12-30 2015-12-30 Glucagon derivatives

Publications (1)

Publication Number Publication Date
ZA201704328B true ZA201704328B (en) 2021-01-27

Family

ID=56284668

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/04328A ZA201704328B (en) 2014-12-30 2017-06-26 Glucagon derivatives

Country Status (18)

Country Link
US (3) US10513550B2 (OSRAM)
EP (1) EP3240802B1 (OSRAM)
JP (1) JP6758297B2 (OSRAM)
KR (1) KR102418477B1 (OSRAM)
CN (1) CN107250155B (OSRAM)
AR (1) AR103323A1 (OSRAM)
AU (1) AU2015372767B2 (OSRAM)
BR (1) BR112017013845A2 (OSRAM)
CA (1) CA2972001C (OSRAM)
EA (1) EA036479B1 (OSRAM)
IL (1) IL253001B (OSRAM)
MX (1) MX389593B (OSRAM)
PH (1) PH12017501205A1 (OSRAM)
SG (2) SG10201906912VA (OSRAM)
TW (1) TWI696631B (OSRAM)
UA (1) UA122967C2 (OSRAM)
WO (1) WO2016108617A1 (OSRAM)
ZA (1) ZA201704328B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3575314B1 (en) * 2014-12-30 2024-02-14 Hanmi Pharm. Co., Ltd. Glucagon derivative
EP3322437B1 (en) 2015-06-30 2024-01-17 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN116059389A (zh) 2015-12-31 2023-05-05 韩美药品株式会社 胰高血糖素/glp-1/gip受体三重激动剂的长效缀合物
EP4572782A1 (en) 2022-08-18 2025-06-25 Boehringer Ingelheim International GmbH Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1060746A4 (en) 1998-03-06 2002-06-19 Chugai Pharmaceutical Co Ltd PROTEIN-FREE PREPARATIONS
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
DK1682583T3 (da) 2003-11-13 2012-05-07 Hanmi Holdings Co Ltd Proteinkompleksdannelse under anvendelse af immunoglobulinfragment samt fremgangsmåde til fremstilling deraf
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR20070094909A (ko) 2004-12-02 2007-09-27 도만티스 리미티드 혈청 알부민 및 glp-1 또는 pyy를 표적으로 삼는이중특이성 도메인을 갖는 항체
EP2390264A1 (en) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable propperties
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
SI1891105T1 (sl) 2005-06-13 2012-07-31 Imp Innovations Ltd Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2007030375A2 (en) 2005-09-08 2007-03-15 Children's Hospital Medical Center Lysosomal acid lipase therapy for nafld and related diseases
WO2007100535A2 (en) * 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
KR100880509B1 (ko) 2006-10-16 2009-01-28 한미약품 주식회사 재조합 단백질의 대량 생산을 위한 신규한 벡터, 발현세포주 및 이를 이용한 재조합 단백질의 생산 방법
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-항진물질
US20100196405A1 (en) 2007-07-10 2010-08-05 Kingman Ng GLP-1 Fc FUSION PROTEIN FORMULATION
CN103416421B (zh) 2007-07-27 2016-07-27 拜尔农作物科学股份公司 三元活性化合物结合物
EP2187525B1 (en) 2007-08-07 2014-03-12 Fujitsu Limited Error detection device, and error correction/error detection decoding device and method
AU2008306141A1 (en) 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Thyrotropin releasing hormone for therapeutic applications
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
EP2214700A4 (en) 2007-11-02 2012-08-22 Janssen Biotech Inc HALF-SYNTHETIC GLP-1 PEPTIDE FUSION CONSTRUCTS, METHOD AND USES
US20110065633A1 (en) 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
JP5775450B2 (ja) 2008-06-17 2015-09-09 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation グルカゴン/glp−1受容体コアゴニスト
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation 生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US20110171312A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
FR2936441B1 (fr) 2008-09-26 2012-12-07 Rhodia Operations Article polyamide composite
DK2370461T3 (da) * 2008-12-15 2013-12-16 Zealand Pharma As Glucagonanaloger
WO2010071807A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
EP3178835B1 (en) 2009-02-03 2019-04-10 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
MY150536A (en) 2009-03-20 2014-01-30 Hanmi Science Co Ltd Method for preparing a site-specific physiologically active polypeptide conjugate
US8734796B2 (en) 2009-03-20 2014-05-27 Amgen Inc. Carrier immunoglobulins
BRPI1014508A2 (pt) 2009-06-16 2016-04-05 Univ Indiana Res & Tech Corp análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso"
JP6054742B2 (ja) * 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
WO2011075393A2 (en) * 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
EA026384B1 (ru) * 2010-01-20 2017-04-28 Зилэнд Фарма А/С Лечение заболеваний сердца
BR112012018585A2 (pt) 2010-01-27 2017-01-10 Univ Indiana Res & Tech Corp conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade
AU2011231503C1 (en) * 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
JP5282146B2 (ja) 2010-09-06 2013-09-04 パナソニック株式会社 表示装置及びその制御方法
CN101974077A (zh) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 一种新颖的多肽化合物
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
KR101767570B1 (ko) 2010-10-26 2017-08-14 한미사이언스 주식회사 항 비만 펩타이드의 지속형 결합체
CN102010473A (zh) 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
AR084558A1 (es) 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
JP6118500B2 (ja) 2011-02-28 2017-04-19 ローム アンド ハース エレクトロニック マテリアルズ エルエルシーRohm and Haas Electronic Materials LLC フォトレジスト組成物、およびフォトリソグラフィパターンを形成する方法
KR101161526B1 (ko) 2011-05-16 2012-07-02 숭실대학교산학협력단 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
ES2692187T3 (es) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de obesidad que lo comprende
PH12013502517A1 (en) 2011-06-17 2014-01-20 Hanmi Science Co Ltd A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof
US8729017B2 (en) 2011-06-22 2014-05-20 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
MX2014012625A (es) 2012-04-19 2015-05-15 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos para su produccion.
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
KR101373563B1 (ko) 2012-07-25 2014-03-12 전북대학교산학협력단 Tof-mra를 이용한 혈류특성 및 mr-신호강도구배(전단율) 유도방법
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
ES2748158T3 (es) 2012-11-06 2020-03-13 Hanmi Pharm Ind Co Ltd Formulación líquida de conjugado de proteínas que comprende la oxintomodulina y un fragmento de inmunoglobulina
PL2986313T3 (pl) * 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
JP6137046B2 (ja) 2014-05-09 2017-05-31 信越化学工業株式会社 単量体、高分子化合物、レジスト材料及びパターン形成方法
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
WO2019171352A2 (en) 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity

Also Published As

Publication number Publication date
CA2972001C (en) 2024-07-02
AU2015372767A1 (en) 2017-07-13
US12018060B2 (en) 2024-06-25
UA122967C2 (uk) 2021-01-27
MX389593B (es) 2025-03-20
IL253001B (en) 2022-04-01
MX2017008715A (es) 2017-11-17
CN107250155B (zh) 2021-08-10
US20220025012A1 (en) 2022-01-27
EP3240802A1 (en) 2017-11-08
KR102418477B1 (ko) 2022-07-08
JP2018505153A (ja) 2018-02-22
EA036479B1 (ru) 2020-11-16
EA201791498A1 (ru) 2017-10-31
IL253001A0 (en) 2017-08-31
US20200140515A1 (en) 2020-05-07
US10513550B2 (en) 2019-12-24
TWI696631B (zh) 2020-06-21
SG11201705130XA (en) 2017-07-28
SG10201906912VA (en) 2019-09-27
TW201632546A (zh) 2016-09-16
PH12017501205A1 (en) 2017-10-18
US11254724B2 (en) 2022-02-22
AU2015372767B2 (en) 2020-07-16
NZ733649A (en) 2024-07-26
KR20160082026A (ko) 2016-07-08
JP6758297B2 (ja) 2020-09-23
NZ771617A (en) 2024-09-27
BR112017013845A2 (pt) 2018-01-02
CA2972001A1 (en) 2016-07-07
US20180002395A1 (en) 2018-01-04
AR103323A1 (es) 2017-05-03
EP3240802A4 (en) 2018-10-10
WO2016108617A1 (en) 2016-07-07
CN107250155A (zh) 2017-10-13
HK1246323A1 (en) 2018-09-07
EP3240802B1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
IL281375B (en) Glucagon derivatives have improved stability
GB2534439B (en) Packer
ZA201704602B (en) Dihydroindolizinone derivative
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3418273T3 (pl) Pochodne flawaglin
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
ZA201704328B (en) Glucagon derivatives
IL248629B (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
PL3097076T3 (pl) Nowe pochodne CYP-eikozanoidowe
IL248772A0 (en) A consequence of cyclohexyl pyridine
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
PL3228616T3 (pl) Pochodne pirydyny